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Objective: To determine whether measurement of preoperative serum ear- 
cinoembryonic antigen concentrations adds useful prognostic data to 
current preoperative staging of lung cancer by computed tomography, 
bronchoscopy, and mediastinoscopy. Methods: A prospective cohort study of 
130 consecutive patients was evaluated for suspected lung cancer from July 
1991 through December 1992 at a university-affiliated Veterans Affairs 
Medical Center. Serum concentrations of carcinoembryonic antigen were 
measured before diagnosis, staging, or resection of cancer. Results: Malig- 
nant disease was diagnosed by bronchoscopy, needle biopsy, mediastinos- 
copy, or resection in 111 of 130 patients. In the 50 patients undergoing 
resection with curative intent, multivariate analysis indicated that carcino- 
embryonic antigen was a significant predictor of survival independent of 
patient age, pathologic stage, histologic type, and tumor size (P = .0357). 
Conclusions: Elevated preoperative serum concentrations of carcinoembry- 
onic antigen predict a poor prognosis for lung cancer independent of other 
conventional staging parameters and have an adjunctive role in the staging 
of lung cancer. (J Thorac Cardiovasc Surg 1998;116:412-6) 
A pproximately 50% of patients die within 5 years of resection of lung cancer with curative intent, 
suggesting that the laboratory tests and imaging 
modalities currently used for preoperative staging 
have limited sensitivities to detect unfavorable tu- 
mor biology and disseminated malignant disease. 
Although many serologic and tissue tumor markers 
have been reported to identify unfavorable tumor 
biology, carcinoembryonic antigen (CEA) is a serum 
marker that has the potential to augment current 
staging modalities by identifying advanced lung can- 
cer. 1 CEAs represent a heterogeneous group of 
oncofetal glycoprotein antigens that circulate in 
high concentrations in patients with certain malig- 
nant tumors, especially epithelial tumors. Although 
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serum CEA assays have low sensitivity and specific- 
ity for diagnosing lung cancers, I several reports have 
indicated that elevated preoperative CEA levels are 
associated with more advanced disease and with 
very poor survival after presumptively curative sur- 
gical resection. 24' 
Despite this evidence, the preoperative measure-- 
ment of serum CEA has not been incorporated into 
the staging evaluation of patients considered for 
resection of lung cancer. Because assay of CEA is an 
inexpensive, readily available preoperative serum 
test that may correlate with aspects of tumor biology 
not measured by conventional staging modalities, 
we sought to re-examine in our clinical practice 
whether preoperative measurement of serum CEA 
added useful prognostic data o the current preop- 
erative staging algorithm including computed to- 
mography (CT), bronchoscopy, and mediastinos- 
copy. In addition, we attempted to characterize the 
biologic plausibility of CEA as a predictive tool by 
correlating elevations in serum CEA with tumor 
size, histologic type, and stage. 
Patients and methods 
Selection of patients. From July 1991 through Decem-- 
ber 1992, 142 consecutive patients were evaluated by the 
Pulmonary Medicine Service at the Minneapolis Veterans 
Affairs Medical Center for lung cancer suspected on the 
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basis of abnormal chest radiographs or unexplained he- 
moptysis. Of these, 130 patients gave informed consent o 
phlebotomy of a single blood sample for determination f
serum CEA before bronchoscopy, which was the first 
invasive study performed in all patients. This study was 
approved by the Institutional Review Board on Human 
Studies at the Minneapolis Veterans Affairs Medical 
Center. 
in all 130 patients, the disease was staged by history, 
physical examination, laboratory tests including liver func- 
tion and serum calcium, CT from the chest through the 
adrenal glands, and bronchoscopy. Patients in whom 
advanced isease was suspected on the basis of systemic 
symptoms (especially weight loss), abnormal aboratory 
tests (especially elevations in levels of alkaline phospha- 
tase or calcium), or who had larger or more central tumors 
had additional radiographic studies including CT of the 
head and abdomen and radionuclide bone scans. Solitary 
lesions suggestive of metastatic spread of cancer from 
distant sites were evaluatcd by CT-guided needle biopsy. 
All patients with potentially resectable ung cancer under- 
went exploration by mediastinoscopy and intraoperative 
bronchoscopy before thoracotomy. Contralateral lymph 
nodes wcre sampled during mediastinoscopy, and medi- 
astinal ymph node dissection was performed for pneumo- 
ncctomy and lobectomy cases. Thoracic surgeons and 
patients were kept blinded to the results of CEA deter- 
minations throughout the study. All thoracotomies were 
performed within 4 weeks of the serum CEA measure- 
mcnts. 
Patient demographic data and pathology reports were 
obtained from the hospital computer database. Date of 
last contact or date of death was obtained by scanning the 
hospital computer database and tumor registry for admis- 
sions, outpatient visits, and dates of death. For patients 
who could not be clearly identified as alive (outpatient or 
inpatient visit within the past 2 months) or dead from the 
hospital computer ecords, the Veterans Administration 
Beneficiary Identification and Records Locator System 
database was used to ascertain dates of death. 
CEA assay. Blood was allowed to clot, and serum was 
separated by centrifugation and frozen at -20°C until 
assayed. Serum CEA was measured by means of the 
Tandem solid-phase 2-site radioimmunoassay (Hybritech 
Inc, San Diego, Calif'). The detection limit of the assay was 
1 ng/mL, with within-run and between-run coefficients of 
variation of 5.9% and 6.9%, respectively. According to the 
manufacturer, the upper limit of normal for this assay for 
healthy individuals was 3 ng/mL; serum CEA values 
exceeded 5 ng/mL and 10 ng/mL, respectively, in 11% and 
7% of patients with malignant pulmonary disease. 
Statistical analysis. The following analytic approach 
was taken to assess whether preoperative CEA levels add 
useful prognostic information about length of survival 
beyond that supplied by the standard prognostic variables 
of pathologic stage, tumor size, histologic type, and pa- 
tient age at the time of operation. This analysis included 
only those patients who underwent surgical resection of 
their tumor (n = 50). Pathologic stage was dichotomized 
into stage 3 or higher versus stages 1 and 2. Histologic 
typc was categorized as adenocarcinoma, squamous cell 
carcinoma, or other. The date of operation was included 
Table I. Estimated probability of 3-year survival Jbr 
stage 1 and 2 squamous cell and adenocarcinoma 
by preoperative CEA level 
Serum CEA Squamous cell 
(ng/ml) carcinoma * Adenocarcinoma * 
1 0.58 (0.41, 0.83) 0.46 (0.22, 0.94) 
4 0.50 (0.32, 0.78) 0.37 (0.16, 0.86) 
7 0.41 (0.22, 0.78) 0.28 (0.09, 0.81) 
10 0.32 (0.13, 0.79) 0.19 (0.05, 0.81) 
14 0.20 (0.04, 0.97) 0.10 (0.01, 0.99) 
*Numbers in parentheses are95% confidence intervals. 
in the models to control for any possible bias that would 
be introduced as a result of the differing lengths of time at 
risk. Survival was calculated from the date of operation to 
the date of death or last contact. A Cox proportional 
hazards model was fitted to the data incorporating the 
covariates ( tage, tumor size, histologic type, age, and date 
of operation) other than CEA. CEA was then added to 
the model, after diagnostics examining plots of residuals 
and tests for power transformations indicated that the 
only useful transformation was rounding the CEA level to 
the nearest integer (CEA values > 25 were coded as 25). 
The likelihood ratio test was used to compare the differ- 
ence in the two models (with and without CEA). Risk 
ratios and 95% confidence intervals were derived from the 
model. Interaction terms between CEA and histologic 
type, size, and stage were subsequently introduced into 
the model but were not significant and arc not presented 
here. From the model we also derived estimates of the 
effect of various CEA levels on 3-year survival for patients 
with stage 1 and 2 squamous cell carcinoma nd adeno- 
carcinoma separately, using the observed mean value for 
the other covariates. 
To study the biologic plausibility of CEA as a prognos- 
tic indicator in lung cancer, we investigated univariate 
associations between CEA and histologic type, surgical 
stage, tumor size, and liver function tests. Because of the 
skewed distribution of serum CEA concentrations, me- 
dian values are presented and associations of serum CEA 
concentrations with histologic type and TNM stage were 
analyzed by Kruskal-Wallis 1-way analysis of variance with 
post hoc comparisons by Wilcoxon rank sum tests. Asso- 
ciations between serum CEA concentrations and tumor 
size were by Pearson bivariate correlation. Analyses were 
performed by means of SPSS for Windows (release 6.1, 
Chicago, Ill) and SAS (release 6.11, SAS Inc, Cary, NC). 
All P values are two-tailed. 
Results 
Between July 1991 and December  1992, 130 of 
142 consecutive patients evaluated for suspected 
lung cancer consented to have serum CEA concen- 
trat ions measured before diagnostic procedures.  In 
111 (109 male, 2 female) of these 130 patients, a 
diagnosis of mal ignant disease was made by bron- 
choscopy, needle biopsy, mediast inoscopy, or resec- 
tion. Sixteen patients were considered not to be 
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Table II. Association of serum CEA and 
histologic type 
Resected cases Total malignant cases 
CEA: CEA: 
Histology No. median (range) No. median (range) 
Adenocarcinoma 21 6.1 (1.3-910.0) 38 7.3t" (1.3-910.0) 
Squamous cell 22 3.9 (0-14.6) 39 3.7 (0-16.1) 
Large cell 4 4.1 (1.3-6.9) 15 2.9 (1.3-6.9) 
Small cell 1 6 14 6.41" (2.2-462.0) 
Other* 2 1.3 (0.1-2.5) 5 2.3 (0.1-4.0) 
Total 50 111 
*Solitary metastatic carcinoma nd lymphoma. 
?P < .01 compared with squamous cell and large ceil carcinoma. 
surgical candidates because of preoperative histo- 
logic studies howing small cell (13 patients), lym- 
phoma (2 patients), or metastatic adenocarcinoma 
(1 patient). An additional 43 patients had advanced 
non-small cell lung cancer determined by the stag- 
ing methods described under Patients and methods' 
(unresectable stage 3A, 2 patients; stage 3B, 23 
patients; stage 4, 18 patients). Two additional pa- 
tients were precluded from surgery because of se- 
vere lung disease. Thus 50 of 130 study patients with 
suspected malignancy had apparently limited lung 
cancer after a full staging evaluation and were taken 
to thoracotomy for resection. These 50 resections 
included 8pneumonectomies, 39 lobectomies, and 3 
wedge resections. Resection margins were histolog- 
ically free of tumor in all cases. All 3 patients 
undergoing wedge resections (because of limited 
cardiopulmonary reserve) had TI lesions with no 
evidence of nodal disease. 
In a multivariate analysis of the 50 resected cases, 
we evaluated the utility of preoperative CEA as a 
predictor of long-term survival, as described under 
Patients and methods'. The likelihood ratio test com- 
paring the Cox proportional hazards model, first 
without and then with CEA added as a covariate to 
the model, indicated that CEA was a significant 
predictor of survival independent of patient age, 
pathologic stage, histologic type, and tumor size 
(P = .0357). The model-estimated risk ratio for 
CEA level is 1.086 (95% CI: 1.009, 1.169), indicating 
that for each increase of CEA of 1 ng/mL, the 
hazard (risk) of death increases by 8.6%. Estimated 
probabilities of 3-year survival by CEA level for 
stage 1 and 2 adenocarcinoma and squamous cell 
carcinoma re shown in Table I. For example, the 
estimated probability of surviving 3 years after sur- 
gery for patients with stage 1 or 2 squamous cell 
carcinoma is approximately 60% for those with 
preoperative CEA levels less than 2 ng/mL, but only 
40% for those with CEA levels of 7 ng/mL, and 20% 
for those with CEA levels of 14 ng/mL. For patients 
with stage 1 or 2 adenocarcinoma, the 3-year sur- 
vival probabilities for these three levels of CEA are 
approximately 45%, 30%, and 10%, respectively. 
However, the confidence intervals around these 
survival probability estimates are wide because of 
the relatively small number of cases available for 
analysis. 
To understand the biologic plausibility of CEA as 
a predictive tool, we correlated elevations in serum 
CEA with histologic type, tumor size, and stage. For 
the total 111 malignant cases, median preoperative 
serum CEA concentrations were significantly higher 
for adenocarcinoma and small cell carcinoma than 
for large cell or squamous cell carcinoma (Table II). 
For the 50 resected cancers, the association between 
median serum CEA concentrations and histologic 
types was not statistically significant, likely because 
of the small numbers of cases. Because serum CEA 
concentrations can be elevated by a combination of 
increased numbers or synthetic rates of malignant 
cells and decreased clearance through the liver, we 
hypothesized that serum CEA in patients with lung 
cancer might be correlated with measures of tumor 
mass or with hepatic function. However, no signifi- 
cant association between tumor size and serum 
CEA concentration was identified by Pearson biva- 
riate correlation. Similarly, median serum CEA 
concentrations were not significantly associated with 
TNM stage for either the total 111 malignant cases 
or for the 50 resected cases (Table III). With regard 
to hepatic learance, serum CEA concentrations did 
not correlate with other metabolic tests of liver 
function, including serum aspartate aminotransfer- 
ase, bilirubin, alkaline phosphatase, or albumin (not 
shown). 
Discussion 
When applied to a consecutive series of patients 
evaluated for suspected lung cancer, preoperative 
serum CEA provided additional prognostic infor- 
mation independent of patient age, pathologic 
stage, histologic type, and tumor size. Despite the 
small numbers of cases in our study, elevated pre- 
operative serum CEA was associated with a clini- 
cally and statistically significant reduction in survival 
after intended curative resection. Thus, despite cur- 
rent advanced imaging modalities and diagnostic 
procedures for preoperative staging of lung cancer, 
our data support previous studies that have uni- 
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formly indicated a role for preoperative serum CEA 
as an adjunct o conventional modalities for staging 
lung cancer. 4-1° 
The biologic basis for the association between 
serum CEA and survival in lung cancer remains 
obscure. Serum CEA is related to tumor histologic 
type. We found significantly higher serum CEA 
concentrations in adenocarcinomas nd small cell 
carcinomas than in large cell and squamous cell 
carcinomas, in agreement with previous re- 
ports. 7'8'm'1~ Interestingly, tumor production of 
CEA measured by immunocytochemical staining or 
assay of tumor cytosolic concentrations does not 
correlate with sermn CEA concentrations and does 
not predict survival in lung cancer, even when 
simultaneously measured serum CEA levels 
do.2, 9, 12 In addition to the weak relationship be- 
tween cellular production of CEA and serum levels, 
we and others found no significant association with 
primary tumor size and serum CEA concentra- 
tions.4, 5 Although serum CEA may reflect produc- 
tion by tumor at other sites, we found no significant 
association between TNM stage and serum CEA 
concentrations in 130 cases, in agreement with other 
studies.< 6,7 in addition, one autopsy study of pa- 
tients with lung cancer concluded that serum CEA 
concentrations are not related to the number of 
organs involved or the sites of metastatic ancer. 5 
Serum CEA is cleared primarily by the liver and is 
thought to be elevated in colorectal carcinoma in 
cases of liver metastases. However, we found no 
association between liver function tests and serum 
CEA concentrations. Given the size of our study, we 
cannot definitively exclude a contribution of some of 
these factors to net serum CEA concentrations. At
present, we can only conclude from our study and 
from published investigations that the exact mecha- 
nism of elevated serum CEA concentrations in lung 
cancers remains unclear. 
In summary, serum CEA has all of the properties 
desired for a biologic measure to be used as a 
prognostic indicator in the clinical evaluation of 
lung cancer. It is objective, reproducible, and can be 
evaluated before the operation. Although a number 
of other serum tumor markers, including tissue 
polypeptide antigen and CA-125, appear to also 
have prognostic utility in the preoperative valua- 
tion of lung cancer, 9 currently serum CEA is the 
only one of these that is inexpensive and routinely 
available. Serum CEA also has distinct advantages 
over the variety of other tumor markers that are 
being investigated to better understand lung cancer 
Table III. Association of serum CEA with clinical 
or surgical stage 
Resected cases Total malignant cases 
CEA: CEA: 
Stage No. median (range) No. median (range) 
1 28 3.2 (0-109.0) 28 3.2 (0-109.0) 
2 7 4.2 (1.3-11.9) 7 4.2 (1.3-11.9) 
3A 10 5.4 (2.5-910.0) 12 5.2 (1.7-910.0) 
3B 5 6.2 (2-14.6) 28 3.6 (1.8-366.0) 
4 0 0 18 4.7 (0.7-35.5) 
Unstaged* 18 3.8 (0.8-462.0) 
Total 50 111 
*Cases of small cell, lymphoma, or metastatic cancer. 
biology. Markers of histologic features, such as 
tumor grade, mitotic index, and vascular invasion, 
and immunocytochemical assays of oncogene prod- 
ucts such as p53, ras, and others, 13 furnish at most 
semiquantitative information, are subject o interob- 
server variation, and require resection of a finite 
volume of tumor for studies to be accomplished. 
Direct genetic studies, such as DNA sequencing and 
polymerase chain reaction single-stranded confor- 
mational polymorphism, are presently available only 
as research tools and have the same limitations. 
Taking together our data and previously pub- 
lished studies, we conclude that routine preopera- 
tive serum CEA measurements are an important 
adjunct to conventional anatomic tumor staging 
algorithms, particularly for patients with adenocar- 
cinoma. Marked elevations of serum CEA are indi- 
cations for full and careful staging despite apparent 
localized disease on chest radiographs and CT, In 
such patients, especially those who are marginal 
surgical candidates due to underlying illnesses, the 
poor prognosis implied by the test may be factored 
into decisions regarding surgical resection. Further 
studies are required to determine whether immedi- 
ate or delayed postoperative adjuvant treatment 
might improve the outcome for these patients. Al- 
though such therapies have not had conclusive 
benefit for patients with non-small cell lung cancer, 
the use of serum tumor markers such as CEA may 
be a superior means of identifying such patients for 
these adjuvant herapies. 
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